Strategikon Pharma has announced that it is expanding the service offerings for their Clinical Maestro business operations platform with two offerings. Strategikon provides a SaaS product license for Clinical Maestro clinical trial RFP planning and budgeting, which includes implementation and training. Due to the effects of the pandemic, clinical trial pipelines have been disrupted by delays and changes to trial designs, increasing the use of remote technologies and tasks.
These two new services offer a Full-Service model and an Operator model. The new Operator model consists of assigning trained experts to assist, or directly operate the Sponsor’s instance of Clinical Maestro to expedite the output delivery. This Operator model is geared towards Biopharmaceutical sponsors who operate at high speed and may not have the trained staff available or the time to run clinical plans, budgets or RFP in Clinical Maestro.
A more robust model is the Clinical Maestro Full Service offering in which the Services team performs the analysis on Strategikon’s internal system and provides the Sponsor with a baseline budget and alternative scenarios, depending on the Sponsor’s requirement.
For more information, read the full release, here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.